The AVENIO Tumor Tissue Targeted Kit is a next-generation sequencing (NGS) assay for comprehensive genomic profiling of solid tumors from formalin-fixed paraffin-embedded (FFPE) tissue samples. It contains 17 guideline-aligned biomarkers, including those in the U.S. National Comprehensive Cancer Network (NCCN).1
Features and Benefits of AVENIO Tumor Tissue Targeted Kits
- Panel content exactly-matched to gene panel in the AVENIO ctDNA Targeted Kit (same genes, gene regions and hybrid-capture workflow) to facilitate analytical concordance between tissue and plasma
- All four mutation classes (SNVs, indels, fusions and CNVs) in a single DNA workflow with exceptional sensitivity and specificity1
- 99% success rate for FFPE tissue samples that pass input QC testing using the AVENIO QC kit included with the assay
- Flexibility to switch between tissue and plasma to support a variety of research applications
- A streamlined, end-to-end workflow from extraction to analysis and reporting in 5 days
- A turnkey solution that includes reagents, intuitive analysis and reporting to facilitate in-house adoption of high performance NGS oncology testing